Ovid Therapeutics Inc. (OVID) financial statements (2020 and earlier)

Company profile

Business Address 1460 BROADWAY
NEW YORK, NY 10036
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:774287
Cash and cash equivalents423687
Short-term investments355 
Other undisclosed cash, cash equivalents, and short-term investments(0)(0) 
Other undisclosed current assets331
Total current assets:804489
Noncurrent Assets
Property, plant and equipment000
Prepaid expense03 
Other noncurrent assets001
Other undisclosed noncurrent assets000
Total noncurrent assets:131
TOTAL ASSETS:814889
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1196
Accounts payable342
Accrued liabilities754
Due to related parties0  
Total current liabilities:1196
Noncurrent Liabilities
Liabilities, other than long-term debt0  
Due to related parties0  
Total noncurrent liabilities:0  
Total liabilities:1196
Stockholders' equity
Stockholders' equity attributable to parent703983
Preferred stock0  
Common stock000
Additional paid in capital283191184
Accumulated other comprehensive income (loss)0(0) 
Accumulated deficit(213)(153)(101)
Total stockholders' equity:703983
TOTAL LIABILITIES AND EQUITY:814889

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Operating expenses(61)(53)(65)
Operating loss:(61)(53)(65)
Nonoperating income110
Net loss available to common stockholders, diluted:(60)(52)(65)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(60)(52)(65)
Other comprehensive income (loss)0(0) 
Comprehensive loss, net of tax, attributable to parent:(60)(52)(65)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: